Literature DB >> 32843409

Elimination of Staphylococcus aureus from the bloodstream using a novel biomimetic sorbent haemoperfusion device.

Malin-Theres Seffer1,2, Gabriele Eden1, Susanne Engelmann2, Jan T Kielstein3.   

Abstract

Removal of bacteria from the blood by means of extracorporeal techniques has been attempted for decades. In late 2019, the European Union licensed the first ever haemoperfusion device for removal of bacteria from the blood. The active ingredient of Seraph 100 Microbind Affinity Blood Filter is ultrahigh molecular weight polyethylene beads with endpoint-attached heparin. Bacteria have been shown to bind to heparin as they would usually do to the heparan sulfate on the cell surface, thereby being removed from the blood stream. We describe the first case of a female chronic haemodialysis patient in which this device was clinically used for a Staphylococcus aureus infection that persisted for 4 days despite antibiotic therapy. After a single treatment, the bacterial load decreased and the blood cultures at the end of a 4 hour haemoperfusion exhibited no bacterial growth. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dialysis; drugs: infectious diseases; infections; therapeutic indications

Mesh:

Year:  2020        PMID: 32843409      PMCID: PMC7449289          DOI: 10.1136/bcr-2020-235262

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study.

Authors:  Michael Allon; Thomas A Depner; Milena Radeva; James Bailey; Srinivasan Beddhu; David Butterly; Daniel W Coyne; Jennifer J Gassman; Allen M Kaufman; George A Kaysen; Julia A Lewis; Steve J Schwab
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

2.  Improved treatment of systemic blood infections using antibiotics with extracorporeal opsonin hemoadsorption.

Authors:  Tohid F Didar; Mark J Cartwright; Martin Rottman; Amanda R Graveline; Nazita Gamini; Alexander L Watters; Daniel C Leslie; Tadanori Mammoto; Melissa J Rodas; Joo H Kang; Anna Waterhouse; Benjamin T Seiler; Patrick Lombardo; Elisabet I Qendro; Michael Super; Donald E Ingber
Journal:  Biomaterials       Date:  2015-07-26       Impact factor: 12.479

3.  Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.

Authors:  Blanche M Chavers; Craig A Solid; David T Gilbertson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2007-01-24       Impact factor: 10.121

4.  Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood.

Authors:  Jung-Jae Lee; Kyung Jae Jeong; Michinao Hashimoto; Albert H Kwon; Alina Rwei; Sahadev A Shankarappa; Jonathan H Tsui; Daniel S Kohane
Journal:  Nano Lett       Date:  2013-01-31       Impact factor: 11.189

5.  Highly efficient enzyme-functionalized porous zirconia microtubes for bacteria filtration.

Authors:  Stephen Kroll; Christoph Brandes; Julia Wehling; Laura Treccani; Georg Grathwohl; Kurosch Rezwan
Journal:  Environ Sci Technol       Date:  2012-08-06       Impact factor: 9.028

6.  National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014.

Authors:  Duc B Nguyen; Alicia Shugart; Christi Lines; Ami B Shah; Jonathan Edwards; Daniel Pollock; Dawn Sievert; Priti R Patel
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-29       Impact factor: 8.237

7.  Removal of bacteria from blood by charcoal hemoperfusion.

Authors:  D H Marks; F Medina; S Lee; A Blackmon; S T Schuschereba
Journal:  Biomater Artif Cells Artif Organs       Date:  1988

8.  In vitro elimination of anti-infective drugs by the Seraph® 100 Microbind® affinity blood filter.

Authors:  Julius J Schmidt; Gabriele Eden; Malin-Theres Seffer; Manuela Winkler; Jan T Kielstein
Journal:  Clin Kidney J       Date:  2020-05-21

9.  Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media.

Authors:  Keith McCrea; Robert Ward; Steven P LaRosa
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

Review 10.  Heparin 2.0: A New Approach to the Infection Crisis.

Authors:  Malin-Theres Seffer; Daniel Cottam; Lui G Forni; Jan T Kielstein
Journal:  Blood Purif       Date:  2020-07-02       Impact factor: 2.614

View more
  6 in total

Review 1.  Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis.

Authors:  Marie Ebeyer-Masotta; Tanja Eichhorn; René Weiss; Lucia Lauková; Viktoria Weber
Journal:  Front Cell Dev Biol       Date:  2022-07-06

2.  Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study.

Authors:  Gabriele Eden; Julius J Schmidt; Stefan Büttner; Philipp Kümpers; Carsten Hafer; Alexandros Rovas; Benjamin Florian Koch; Bernhard M W Schmidt; Jan T Kielstein
Journal:  Crit Care       Date:  2022-06-17       Impact factor: 19.334

3.  Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter.

Authors:  Anke Pape; Jan T Kielstein; Tillman Krüger; Thomas Fühner; Reinhard Brunkhorst
Journal:  TH Open       Date:  2021-04-14

4.  Heparin-Functionalized Adsorbents Eliminate Central Effectors of Immunothrombosis, including Platelet Factor 4, High-Mobility Group Box 1 Protein and Histones.

Authors:  Marie Ebeyer-Masotta; Tanja Eichhorn; René Weiss; Vladislav Semak; Lucia Lauková; Michael B Fischer; Viktoria Weber
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

5.  Heparin-based blood purification attenuates organ injury in baboons with Streptococcus pneumoniae pneumonia.

Authors:  Lingye Chen; Bryan D Kraft; Victor L Roggli; Zachary R Healy; Christopher W Woods; Ephraim L Tsalik; Geoffrey S Ginsburg; David M Murdoch; Hagir B Suliman; Claude A Piantadosi; Karen E Welty-Wolf
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-06-09       Impact factor: 6.011

6.  Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry.

Authors:  Julius J Schmidt; Dan Nicolae Borchina; Mariet Van't Klooster; Khalida Bulhan-Soki; Reuben Okioma; Larissa Herbst; Diego Sandoval Rodríguez; Vedran Premužić; Stefan Büttner; Birgit Bader; Wojciech Serednicki; Ewa Zasada; Michael Schmitz; Ralf A Quabach; Maria Hrincheva; Thomas Fühner; Jan T Kielstein
Journal:  Nephrol Dial Transplant       Date:  2022-03-25       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.